BioCentury | May 17, 2019
Product Development

Abeona tackles gene therapy’s problems in cystic fibrosis with chimeric AAVs

As it builds up its preclinical pipeline, Abeona is switching gears to create chimeric AAV vectors that it hopes will do a better job than naturally occurring ones of dialing in the right properties for...
BioCentury | Apr 11, 2016
Company News

Thermo Fisher, HTG Molecular Diagnostics deal

Thermo Fisher granted HTG rights to develop in vitro diagnostic tests for use with Thermo Fisher’s Ion PGM Dx System , which provides genetic variant analysis. Thermo Fisher did not respond to inquiries, and HTG declined...
BioCentury | Dec 7, 2015
Company News

Thermo Fisher, Novartis, Pfizer deal

Thermo Fisher partnered with Novartis and Pfizer to develop and commercialize a universal next-generation sequencing (NGS) companion diagnostic for non-small cell lung cancer (NSCLC). Thermo Fisher will develop the diagnostic using its Ion PGM Dx...
BioCentury | Nov 23, 2015
Tools & Techniques

Editing CF

Vertex Pharmaceuticals Inc. and CRISPR Therapeutics AG are collaborating to see whether CRISPR's gene editing technology can succeed where gene therapies have come up short for cystic fibrosis. The technology is expected to produce more...
BioCentury | Jul 13, 2015
Clinical News

pGM169/GL67A: Phase IIb data

Data from 116 CF patients ages >=12 in the per protocol (PP) population of a double-blind, U.K. Phase IIb trial showed that once-monthly 5 mL inhaled pGM169/GL67A met the primary endpoint of improving percent predicted...
BioCentury | Jul 3, 2015
Clinical News

Inhalable gene therapy meets Phase II endpoint in CF

Data published Thursday in The Lancet Respiratory Medicine from a Phase II study of pGM169/GL67A to treat cystic fibrosis showed that the inhalable gene therapy led to a significant benefit in lung function. The U.K....
BioCentury | Dec 8, 2014
Company News

Thermo Fisher, GlaxoSmithKline, Pfizer deal

Thermo Fisher, GlaxoSmithKline and Pfizer partnered to develop a universal next-generation sequencing test for solid tumors that will serve as a companion diagnostic for multiple programs. Thermo Fisher will develop the test using its Ion...
BioCentury | Oct 27, 2014
Clinical News

Ion PGM Dx System regulatory update

Thermo Fisher received CE mark approval for its Ion PGM Dx System, which provides genetic variant analysis with a DNA sample as small as 10 ng. Thermo Fisher plans to launch the test in the...
BioCentury | Aug 19, 2013
Clinical News

Hospital Acquired Infection regulatory update

Pathogenica said it received CE Mark approval for its HAI BioDetection CE-IVD Kit to identify 17 pathogens and 10 resistance gene families. The 48-sample kit costs €4,500 ($5,999) and is already available through Pathogenica. The...
BioCentury | Oct 22, 2012
Company News

Life Technologies, Vela Diagnostics deal

Life Technologies granted Vela rights to develop and commercialize next-generation, sequencing-based, in vitro clinical diagnostic tests for cancer and infectious diseases on the Ion Personal Genome Machine (PGM) technology. Vela will seek global approval for...
Items per page:
1 - 10 of 16